JMP Securities reaffirmed their outperform rating on shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) in a report released on Monday, Stock Ratings Network.com reports. JMP Securities currently has a $10.00 price objective on the stock. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $6.94 in last trading session, and closed at $6.60, trading in the range of $6.46 – $6.95. The stock showed a positive weekly performance of 1.23%.
Roth Capital reaffirmed their neutral rating on shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) in a report released on Monday, AnalystRatings.NET reports. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) shares closed at $1.54 on last trade day, by gaining 32.76%. Stock 52 week range is $0.65 – $4.00. Company’s market capitalization is $87.93 billion.
The early commercial launch of Gilead Sciences, Inc. (NASDAQ:GILD) hepatitis C pill Sovaldi looks really good. Total prescriptions (TRx) for Sovaldi rose almost 70% to 1,764 for the week ended Jan. 10, according to IMS Health. Previous weeks included the holidays, so too much can be made about the week-over-week growth. Still, the Solvadi scripts to date are impressive and point to early, strong demand for the new Hep C pill. Gilead Sciences, Inc. (NASDAQ:GILD) stock rose 4.06% and finished the last session at $81.58. The EPS of the stock remained 1.55. Company’s market capitalization is $125.09 billion.
MannKind Corporation (NASDAQ:MNKD) COO Hakan Edstrom bought 1,589 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was purchased at an average cost of $4.53 per share, with a total value of $7,198.17. Following the acquisition, the chief operating officer now directly owns 729,685 shares of the company’s stock, valued at approximately $3,305,473. MannKind Corporation (NASDAQ:MNKD) stock closed at $5.56 in last trading session. The 52 week range of the stock is $2.34 – $8.70.